Under Armour Inc Class A vs Zimmer Biomet Holdings Inc — how do they compare? Under Armour Inc Class A trades at $5.09 (market cap $2.26B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 8.2× Under Armour Inc Class A's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| UA | ZBH | |
|---|---|---|
Market Cap | $2.26B | $18.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.88 | $107.71 |
52-Week Low | $3.96 | $79.58 |
Enterprise Value | $3.24B | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Under Armour (UA) is trading at $5.12, down 9.78% with bearish technical signals despite some oversold RSI readings. The company faces significant fundamental challenges with negative net income margins (-9.99%) and declining revenue trends from $5.16B in 2025 to $4.9B in 2026. Recent Q1 2027 results showed a revenue decline of 3% to $1.1B, prompting management to lower full-year revenue guidance amid softer consumer demand in key markets.
The outlook remains challenging with persistent profitability issues and negative cash flow trends. While analyst sentiment shows mixed ratings (38.81% Buy, 49.25% Hold), the stock trades at attractive valuation multiples (P/S 0.45) but faces execution risks in its turnaround strategy. Key risks include competitive pressures, inventory management challenges, and macroeconomic headwinds affecting consumer spending.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Trailing returns across standard periods
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →